Submission Guidelines ONCOLOGY journal, CancerNetwork.com

Article

Print: Peer-reviewed articles and features submitted by healthcare professionals should focus on clinically relevant information, be 1,500-3,500 words; AMA style, inclusive of all author names, any designations/degrees, financial disclosures, submission contract, brief 3-4 line bio with any staff and faculty positions, and headshot. Please allow 1-6 months for the full process, depending on depth and breadth of your submission. 

Digital: Healthcare professional-submitted news articles or blog posts should be 300-500 words.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

The FDA has accepted a new drug application for the prostate-specific membrane antigen PET imaging agent.

FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer

Tim Cortese
August 7th 2025
Article

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

The CAR-T yielded a manageable safety profile in patients with mantle cell lymphoma.

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Tim Cortese
August 7th 2025
Article

The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.